News - OBI Pharma 台灣浩鼎

2024.Jun.12

Corporate

OBI Pharma announces Phase 1/2 study initiation for OBI-992, a TROP2-targeted antibody drug-Conjugate (ADC) for cancer therapy

2024.Jun.07

Corporate

OBI Pharma at BIO USA 2024

2024.Apr.11

Corporate

Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform

2024.Mar.18

Corporate

OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform.

2024.Mar.12

Corporate

OBI Pharma to present the Study Results of OBI-992 at the 14th World ADC London

2024.Mar.11

Corporate

OBI announces the termination of OBI-3424 Phase II trial

2024.Jan.03

Corporate

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992

2023.Dec.29

未分類

Corporate

Kung-Yee Liang, PH.D. was elected as the chairman of OBI Pharma, Inc.

2023.Dec.06

未分類

Corporate

OBI Pharma proprietary ADC technology platform “plug and play”

2023.Nov.23

未分類

Corporate

Award & Certification

OBI Achieves ISO/IEC 27001 International Information Security Certification

Announcements

Latest announcements

Events

Latest events